Pediatric ID Flashcards

1
Q

preventable AOM risk factors

A

child care, smoke exposure, pacifier, bottle-feeding, missed immunizations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

non-preventable AOM risk factors

A

male, older siblings, family history, congenital anomalies, immune deficiency, onset of first episode before 6 months of age, lower socioecononmic status, season

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

otitis media with effusion

A

more common
middle ear fluid is sterile
resolves spontaneously over time
antibiotics are not indicated and are not beneficial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

acute otitis media

A

bacterial infection is likely

antibiotics are indicated if symptomatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

anatomy of the ear

A
tympanic membrane (ear drum) separates middle ear from inner ear
eustachian tube is supposed to drain fluid from ear canal to sinuses - in children, it is shorter and more horizontal - more likely for sinus fluid to move into inner ear canal and cause infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

pathogenosis of AOM

A

ineffective aeration of middle ear space causes eustachian tube dysfunction
inflammation and edema of mucosal linings and narrowing of eustachian tube lumen
resorption of air created vacuum and reverses flow of secretions drawing fluid into middle ear
bacteria multiply in fluid and stimulate inflammatory response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

microbiology of AOM

A

most common: S. pneumo, H. influenzae, moraxella

other organisms include: staph aureus and gram-negative organisms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

clinical signs and symptoms of AOM

A

otalgia (ear pain), holding or tugging at ear, fever, irritability, poor feeding/anorexia, disrupted sleep, malaise, otorrhea, sometimes asymptomatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

diagnosis of AOM

A

requires visualization of tympanic membrane
normal TM: Slightly concave, Pearly gray in color, Translucent, Moves easily in response to pressure
TM in otitis media: Bulging, Nonmobile, Erythematous (not conclusive), Definitive diagnosis is culture of middle ear fluid by tympanocentesis
Certain diagnosis requires:
-Acute onset of clinical signs and symptoms
-Presence of middle ear effusion
-Signs and symptoms of middle ear inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

severity of AOM

A

AOM can be classified as either:
Non-severe: Mild otalgia AND** Fever under 39 ˚C in past 24 hours
Severe: Moderate to severe otalgia OR** Fever ≥ 39˚C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

management of AOM - observation

A

Deferment of antibiotics for 48 – 72 hours
Watch for resolution of symptoms
Provide symptomatic** relief
Decision to observe based on: Child’s age, Diagnostic certainty, Illness severity, Assurance of follow-up

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

criteria for initial antibacterial-agent treatment or observation in children with AOM

A

SEVERE: ALWAYS TREAT
UNDER 6 MONTHS: ALWAYS TREAT
6 mo-2 yr, non-severe and unilateral: observe option
2+ years and non-severe: observe option

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

observation failure

A

Must ensure close follow-up and prompt access to medical care if no improvement
What to do if observation fails:
-Communicate with physician
-Begin antimicrobial therapy
-Continue symptomatic therapy
Safety-Net Antibiotic Prescription (SNAP)
-Parents allow 1-2 days for infection to resolve
-If symptoms persist or worsen, fill prescription

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

antibiotic therapy for AOM

A
Efficacy
Resistance
Oral bioavailability
Middle-ear penetration
Safety
Tolerability
Likelihood of compliance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

resistance

A

Risk factors include child care, recent receipt (less than 30 days) of antibiotic therapy, and age under 2 years
Haemophilus influenzae & Moraxella catarrhalis
-40% of H. flu strains and almost all M. catarrhalis strains are resistant to penicillins
-Due to β-lactamase production*
-Overcome by addition of ß-lactamase inhibitor
Streptococcus pneumoniae
-50% of strains are penicillin resistant
-Due to alterations in penicillin binding proteins
*
-Overcome by higher concentrations of antibiotic at site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

initial/delayed antibiotic treatment

A

1st line: amox or amox/clav

alternative if allergic: cefdinir, cefuroxime, cefpodoxime, ceftriaxone 1 or 3 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

treatment failure after 48-72 hours

A

1st line: amox/clav or ceftriaxone 3 days
alternative if allergic: ceftriaxone 3 days, clindamycin +/- 3rd gen ceph
if failed 2nd abx: clind + 3rd gen ceph
tympanocentesis - consult specialist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

amox dosing for AOM

A

80-90 mg/kg/day in 2 divided doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

amox/clav dosing for AOM

A

90 mg/kg/day amox with 6.4 mg/kg/day clav in 2 divided doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

cefdinir dosing for AOM

A

14 mg/kg/day in 1 or 2 doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

cefuroxime dosing for AOM

A

30 mg/kg/day in 2 divided doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

cefpodoxime dosing for AOM

A

10 mg/kg/day in 2 doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

ceftriaxone dosing for AOM

A

50 mg/kg/day IM or IV daily for 1-3 days

24
Q

clindamycin dosing for AOM

A

30-40 mg/kg/day in 3 doses

25
Q

amoxicillin for AOM

A
First-line therapy - A few exceptions
Advantages:
-Achieves adequate concentrations
-Safe & effective
-Tastes good – “bubblegum medicine” 
-Low cost
Reasons not to use:
-Resistance
-Treatment failure
-PCN allergy
-Type 1 cephalosporin allergy
26
Q

amox-clav for AOM

A

1st choice if amoxicillin not an option and no allergies
Advantages: Additional coverage for ß-lactamase production
Disadvantages:
-Not all formulations are interchangeable
-Must choose appropriate formulation to avoid side effects associated with clavulanate - Main side effect is diarrhea, Dose clavulanate component at ≤ 10 mg/kg/day

27
Q

oral cephalosporins for AOM

A
All are considered 2nd line therapy and good options for treatment failure
Cefdinir (Omnicef®)
-14 mg/kg/day divided q12-24 hours
-Tastes good; but has poor bioavailability
-Not as affordable
Cefuroxime (Ceftin®)
-30 mg/kg/day divided q12 hours
-Tastes bad
-Not as affordable
Cefpodoxime
-10 mg/kg/day divided q12 hours
-Tastes bad
-Not as affordable
28
Q

macrolides for AOM

A
also 2nd line
Azithromycin (Zithromax®)
-Dosing regimen: 30 mg/kg/day x 1 day, 10 mg/kg/day x 3 days OR 10 mg/kg/day x 1 day, then 5 mg/kg/day daily x 4 days
Advantages: Once daily dosing, Short duration of therapy
Disadvantages: Cost, Increased macrolide
resistance
Clarithromycin
-15 mg/kg/day divided q12
hours
-Overall poor tolerability
-Not most cost-effective
option
-Risk of increased macrolide
resistance
29
Q

ceftriaxone for AOM

A
Appropriate in severe
cases when:
-Oral treatment not option
-Initial oral treatment fails
-Highly resistant S.
pneumoniae identified
Dosing:
-Intramuscular administration
-50mg/kg daily
-One dose** initial therapy
-Three doses**- treatment
failure
Advantages: Broad spectrum of activity, Equally effective to 10 days of amoxicillin
Disadvantages: Injection site pain, Cost, Avoid in under 2 mo of age, Cautions (Calcium co-administration, C. difficile associated-dz)
30
Q

duration of therapy for AOM

A

Exact effective duration is unknown
Historical recommendation is 10 days
10 days of therapy is indicated for: Children under 6 years of age; Children with severe illness
Shorter courses (5-7 days) may be used in children ≥ 6 years of age without severe disease

31
Q

adjunctive therapy for AOM

A
Analgesics
-Acetaminophen/ibuprofen
-Benzocaine drops - contraindicated in typanic membrane rupture
-Narcotic analgesics
Decongestants/antihistamines
Dexamethasone
32
Q

follow up for AOM

A

Within days for young infants with severe episode or children of any age with continuing pain
Within 2 weeks for infants or young children with history of frequent recurrences
1 month after initial examination for children with only a sporadic episode of AOM
No follow-up may be necessary for older children

33
Q

prevention of AOM

A
Vaccination
-Pneumococcal
-Influenza
Reduction of preventable risk factors
-Exposure to tobacco smoke
-Limit pacifier use to under 6 months
-Breastfeed until at least 6 months of age
-Avoid supine bottle feeding – “bottle propping”
Prophylaxis
Tympanostomy tubes
34
Q

antibiotic prophylaxis for AOM

A

Antibiotic prophylaxis is controversial due to increased risk of developing resistance
May be helpful to decrease recurrent episodes
May also help to reduce risk of hearing loss
Antibiotics utilized include: Amoxicillin, Sulfasoxazole, Sulfamethoxazole/trimethoprim (Bactrim™)
Use for 6 months during spring and winter

35
Q

tympanostomy tubes

A

Small ventilation tubes inserted through TM to provide drainage for eustachian tubes
Indicated in recurrent AOM despite appropriate medical therapy
-3 or more episodes in under 6 mo
-4 or more episodes in under 12 mo
Advantages
Disadvantages

36
Q

UTI risk factors

A

girls: white, under 12 mo, temp over 39, fever 2+ days, absence of another source of infection - 1 factor = 1% probability; 2 factors = 2% probability of UTI
boys: nonblack, temp over 39, fever 24+ hours, absence of another source of infection, uncircumsized

37
Q

pathogenesis of UTI

A

Retrograde ascent - urethra to bladder
Nosocomial infection - infants
Hematogenous spread
Fistula formation - not in US

38
Q

common pathogens of UTI

A

E coli*** and others

39
Q

s/sxs/diagnosis of UTI

A

evaluate all febrile children 2-24 months
older children should be evaluated if clinical presentation
s/sxs vary by age
-newborns: jaundice, sepsis, failure to thrive, vomiting, fever
-infants/young children: fever, strong-smelling urine, hematuria, abd/flank pain, new onset urinary incontinence
-school-aged children: sxs similar to adults (dysuria, freq and urgency)

40
Q

methods of urine collection

A

Clean catch - Older patient groups
Bag specimen - Unacceptably high rates of false-positive cultures
Catheterization - Preferred for 2-24 month age group
Supra-pubic aspiration - Gold-standard, but INVASIVE

41
Q

urine dipstick

A

Leukocyte esterase = most sensitive single test***
Nitrite - more specific but less sensitive
Blood & Protein - Poor sensitivity and specificity, May be misleading

42
Q

urinalysis

A

Done with culture
Performed on any specimen
-under 1 hour after voiding if kept at room temperature
-under 4 hours after voiding if kept in the refrigerator

43
Q

urine microscopy

A

Pyuria is present

Positive if at least 10 WBCs per µL

44
Q

urine culture

A

Suprapubic aspiration - >1,000 CFU/mL
Catheter specimen - >10,000 CFU/mL
Clean-catch specimen - ≥100,000 CFU/mL

45
Q

UTI treatment

A

Oral and IV options are equally efficacious
Most patients can have oral therapy
Choose IV for patients who are: “Toxic”; Unable to retain oral intake
Can change to oral therapy when patient has clinical improvement – usually within 24-48 hours
Duration of therapy*

46
Q

UTI treatment options

A

Therapy determined using local resistance patterns
Amoxicillin traditional 1st line therapy in past
-E. coli resistance makes it less acceptable choice
-Higher cure rates with trimethoprim/sulfamethoxazole
Oral options: amox, amox/clav, cefixime, cefpodoxime, cefprozil, cephalexin, TMP/SMX
IV options: ceftriaxone, cefotaxime, ceftazidime, gentamicin, tobramycin, piperacillin

47
Q

FQ in children

A

Traditionally not used in children (resistance and risk)
May be useful in some circumstances
-Multidrug-resistant pathogens with no safe alternative
-IV therapy is not feasible
-No other effective oral agent
AAP guidelines recommend FQ use for Pseudomonas or other multidrug-resistant gram-negative bacteria

48
Q

ciprofloxacin

A

Approved for complicated E. coli UTIs and pyelonephritis in patients 1-17 years
will clog G or NG tube - use levo

49
Q

follow up for UTI

A

Considerations for renal/bladder ultrasound and voiding cystography

  • All boys
  • All girls under 3 years of age
  • Girls 3-7 years with fever > 38.5 degC
  • AAP recommends only ultrasound for 2-24 months of age
50
Q

prevention of UTI

A

Efficacy of prophylaxis is questionable
Some clinicians perceive benefit in children with vesicoureteral reflux (VUR) or immunosuppressed
-No benefit found in mild to moderate
-Some benefit with severe VUR
Continuous prophylaxis may not reduce risk of pyelonephritis or renal damage
Cranberry juice? NO

51
Q

RSV

A
One of most common diseases of childhood
Most infants infected during 1st year of life
Characterized by:
-Upper and lower airway disease
-Wheezing
-Reactive airway disease
Re-infection throughout life is common
Most common cause of bronchiolitis
-Inflammation of bronchioles
-Airway edema
-Bronchospasm
-Epithelial lining necrosis
Incubation period 2-8 days
-Symptoms may persist for up to one month
52
Q

RSV risk factors

A
Age under 6 months
Pre-term birth
Cyanotic or complicated CHD
Chronic lung disease
Weakened immune system
53
Q

clinical presentation of RSV

A

Cold-like symptoms

  • Low-grade fever
  • Rhinorrhea
  • Increased work of breathing
  • Can progress to respiratory failure in some cases
54
Q

treatment of RSV

A
Supportive therapy**
-Oxygen
-Hydration
-Mechanical ventilation
-ECMO
β-adrenergic agonist - could help, continue if it is, but no data
Corticosteroids - no data
55
Q

palivizumab

A

Only licensed product for prevention of RSV
Humanized murine monoclonal antibody - NOT a vaccine*** - do NOT need consent
Give 1st dose prior to hospital discharge
Primary benefit is a decrease in the rate of RSV associated hospitalization
Discontinue prophylaxis if patient experiences RSV infection requiring hospitalization
Not indicated for treatment of RSV

56
Q

palivizumab criteria

A

GA under 29 weeks and under 12 mo old
GA under 32 weks w CLD (chronic lung disease of prematurity - Requirement of >21% oxygen for at least the first 28 days of life) and under 12 mo old
Meet above definition of CLD and require chronic steroids, diuretics, or O2 during second year of life and under 24 mo old
hemodynamically significant CHD (Acyanotic heart disease receiving medication to control heart failure symptoms; moderate to severe pulmonary HTN; +/-cyanotic lesions) and under 12 mo old
profound immunocompromise (SCT, SOT, SCID) and under 24 mo old
MAX 5 doses/season

57
Q

dosing and cost considerations of palivizumab

A

15mg/kg IM every month x up to 5 doses/season
50 mg/0.5 ml vial - $1,034.92
100 mg/1 ml vial - $2,069.84
Insurance will restrict to max of 5 doses with new guidelines